Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral ...

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

The randomized, phase 3 study is enrolling patients with metastatic kidney cancer who are initially treated with an ...

Ghia P, Barr PM, Allan JN, et al. Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin ...

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

Jill Feldman discusses the background of the phase 2 COCOON trial in advanced non–small cell lung cancer with EGFR mutations.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

The KEYNOTE-689 study showed pembrolizumab with standard of care significantly improved outcomes for resectable HNSCC, ...